n(g),n(g')-dimethyl-l-arginine has been researched along with Hyperglycemia in 14 studies
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine
Hyperglycemia: Abnormally high BLOOD GLUCOSE level.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We examined whether endogenous inhibitors of NO synthesis are involved in the augmentation of intimal hyperplasia in rabbits with hyperglycaemia induced by alloxan." | 7.70 | Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxan-induced hyperglycaemia. ( Azuma, H; Goto, M; Masuda, H; Tamaoki, S, 1999) |
| " Postprandial alterations in arginine and ADMA:arginine also suggest that acute hyperglycemia may induce VED by decreasing NO bioavailability through an oxidative stress-dependent mechanism." | 6.76 | Postprandial hyperglycemia impairs vascular endothelial function in healthy men by inducing lipid peroxidation and increasing asymmetric dimethylarginine:arginine. ( Ballard, KD; Bruno, RS; Mah, E; Matos, ME; Noh, SK; Volek, JS, 2011) |
| "We aimed to evaluate plasma asymmetric dimethylarginine (ADMA) concentrations and its relation with insulin sensitivity/resistance indices in pregnant women with different degrees of carbohydrate intolerance." | 3.77 | Asymmetric dimethylarginine level in hyperglycemic gestation. ( Kafkasli, A; Karabulut, AB; Sertkaya, AC; Turkcuoglu, I, 2011) |
| " We examined whether endogenous inhibitors of NO synthesis are involved in the augmentation of intimal hyperplasia in rabbits with hyperglycaemia induced by alloxan." | 3.70 | Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxan-induced hyperglycaemia. ( Azuma, H; Goto, M; Masuda, H; Tamaoki, S, 1999) |
| " Postprandial alterations in arginine and ADMA:arginine also suggest that acute hyperglycemia may induce VED by decreasing NO bioavailability through an oxidative stress-dependent mechanism." | 2.76 | Postprandial hyperglycemia impairs vascular endothelial function in healthy men by inducing lipid peroxidation and increasing asymmetric dimethylarginine:arginine. ( Ballard, KD; Bruno, RS; Mah, E; Matos, ME; Noh, SK; Volek, JS, 2011) |
| "Chronic hyperglycemia is a major contributor to in vivo platelet activation in diabetes mellitus." | 2.75 | Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. ( Averna, M; Ciabattoni, G; Consoli, A; Davì, G; Di Fulvio, P; Formoso, G; Ganci, A; Lattanzio, S; Lauro, R; Miccoli, R; Patrono, C; Pulizzi, N; Santilli, F; Sbraccia, P, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Kaneko, YK | 3 |
| Morioka, A | 3 |
| Sano, M | 3 |
| Tashiro, M | 3 |
| Watanabe, N | 3 |
| Kasahara, N | 3 |
| Nojiri, M | 3 |
| Ishiwatari, C | 3 |
| Ichinose, K | 3 |
| Minami, A | 3 |
| Suzuki, T | 3 |
| Yamaguchi, M | 3 |
| Kimura, T | 3 |
| Ishikawa, T | 3 |
| Ballard, KD | 3 |
| Mah, E | 3 |
| Guo, Y | 1 |
| Pei, R | 1 |
| Volek, JS | 3 |
| Bruno, RS | 3 |
| Začiragić, A | 1 |
| Huskić, J | 1 |
| Mulabegović, N | 1 |
| Avdagić, N | 1 |
| Valjevac, A | 1 |
| Hasić, S | 1 |
| Jadrić, R | 1 |
| Takaya, J | 1 |
| Tanabe, Y | 1 |
| Kuroyanagi, Y | 1 |
| Kaneko, K | 1 |
| Lu, CW | 1 |
| Guo, Z | 1 |
| Feng, M | 1 |
| Wu, ZZ | 1 |
| He, ZM | 1 |
| Xiong, Y | 1 |
| Santilli, F | 1 |
| Formoso, G | 1 |
| Sbraccia, P | 1 |
| Averna, M | 1 |
| Miccoli, R | 1 |
| Di Fulvio, P | 1 |
| Ganci, A | 1 |
| Pulizzi, N | 1 |
| Lattanzio, S | 1 |
| Ciabattoni, G | 1 |
| Consoli, A | 1 |
| Lauro, R | 1 |
| Patrono, C | 1 |
| Davì, G | 1 |
| Siervo, M | 2 |
| Corander, M | 2 |
| Stranges, S | 1 |
| Bluck, L | 1 |
| Mander, AP | 1 |
| Browning, LM | 1 |
| Jebb, SA | 1 |
| Sertkaya, AC | 1 |
| Kafkasli, A | 1 |
| Turkcuoglu, I | 1 |
| Karabulut, AB | 1 |
| Noh, SK | 2 |
| Matos, ME | 1 |
| Park, HJ | 1 |
| Yasuda, S | 1 |
| Miyazaki, S | 1 |
| Kanda, M | 1 |
| Goto, Y | 1 |
| Suzuki, M | 1 |
| Harano, Y | 1 |
| Nonogi, H | 1 |
| Ding, H | 1 |
| Triggle, CR | 1 |
| Masuda, H | 1 |
| Goto, M | 1 |
| Tamaoki, S | 1 |
| Azuma, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Fat[NCT02482610] | 22 participants (Actual) | Interventional | 2016-06-30 | Completed | |||
| Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Milk[NCT02482675] | 23 participants (Actual) | Interventional | 2015-06-30 | Completed | |||
| Vasoprotective Activities of Low-Fat Milk in Individuals With Metabolic Syndrome[NCT01411293] | 21 participants (Actual) | Interventional | 2011-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Biomarker of nitric oxide homeostasis is based on the assessment of total nitrite and nitrate concentrations. Changes relative to baseline were used to calculate area under the curve of total nitric oxide metabolites from 0-180 min, i.e. Area Under the Curve (AUC) of change from baseline in nitric oxide homeostasis from 0 min to 180 min (i.e., AUC (NOx 0 min- 0 min, NOx 30 min-0 min, NOx 60 min-0 min, etc) (NCT02482610)
Timeframe: Area under curve of nitrite/nitrate for three hours (0, 30, 60, 90, 120, 150, and 180 min)
| Intervention | umol/L*min (Mean) |
|---|---|
| Glucose | -2229 |
| Glucose With Whole Fat Milk | -1240 |
| Glucose With Non-fat Milk | -1221 |
Glucose concentrations evaluated on the basis as change from baseline to calculate glucose area under the curve from 0-180 min, i.e. Area Under the Curve (AUC) of change from baseline in glucose from 0 min to 180 min (i.e., AUC (glucose 0 min- 0 min, glucose 30 min-0 min, glucose 60 min-0 min, etc) (NCT02482610)
Timeframe: Area under curve of glucose for three hours (0, 30, 60, 90, 120, 150, and 180 min)
| Intervention | mg/dL*min (Mean) |
|---|---|
| Glucose | 6259 |
| Glucose With Whole Fat Milk | 4481 |
| Glucose With Non-fat Milk | 3408 |
MDA concentrations evaluated on the basis as change from baseline to calculate MDAarea under the curve from 0-180 min, i.e. Area Under the Curve (AUC) of change from baseline in MDA from 0 min to 180 min (i.e., AUC (MDA 0 min- 0 min, MDA 30 min-0 min, MDA 60 min-0 min, etc) (NCT02482610)
Timeframe: Area under curve of MDA for three hours (0, 30, 60, 90, 120, 150, 180 min)
| Intervention | umol/L*min (Mean) |
|---|---|
| Glucose | 54.9 |
| Glucose With Whole Fat Milk | 25.78 |
| Glucose With Non-fat Milk | 31.3 |
Flow mediated dilation (FMD) evaluated on the basis as change from baseline to calculate FMD area under the curve from 0-180 min, i.e. i.e. Area Under the Curve (AUC) of change from baseline in FMD from 0 min to 180 min (i.e., AUC (FMD 0 min- 0 min, FMD 30 min-0 min, FMD 60 min-0 min, etc) (NCT02482610)
Timeframe: Area under curve of FMD for three hours (0, 30, 60, 90, 120, 150, and 180 min)
| Intervention | %*min (Mean) |
|---|---|
| Glucose | -195.9 |
| Glucose With Whole Fat Milk | -6.181 |
| Glucose With Non-fat Milk | -5.629 |
Plasma 8-isoprostaglandin-F2a concentration, calculated as 8-isoprostaglandin-F2a AUC from 0-180 minutes (NCT02482675)
Timeframe: 8-isoprostaglandin-F2a area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | pg/mL*min (Mean) |
|---|---|
| Glucose | 2162.2 |
| Glucose With Non-fat Milk | -824.14 |
| Glucose With Whey Protein Isolate | -18.75 |
| Glucose With Sodium Caseinate | 229.14 |
Plasma 8-isoprostaglandin-F2a/Arachidonic acid concentration, calculated as 8-isoprostaglandin-F2a/Arachidonic acid AUC from 0-180 minutes (NCT02482675)
Timeframe: 8-isoprostaglandin-F2a/Arachidonic acid area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | (pg/mL)/(ug/mL)*min (Mean) |
|---|---|
| Glucose | 10129 |
| Glucose With Non-fat Milk | -1655.2 |
| Glucose With Whey Protein Isolate | 2422.3 |
| Glucose With Sodium Caseinate | 3907.6 |
Arachidonic acid concentration, calculated as Arachidonic acid AUC from 0-180 minutes (NCT02482675)
Timeframe: Arachidonic acid area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | ug/mL*min (Mean) |
|---|---|
| Glucose | -2570 |
| Glucose With Non-fat Milk | -1358.4 |
| Glucose With Whey Protein Isolate | -2762.6 |
| Glucose With Sodium Caseinate | -2752.0 |
Plasma arginine concentration, calculated as ARG AUC from 0-180 minutes (NCT02482675)
Timeframe: ARG area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | umol/L*min (Mean) |
|---|---|
| Glucose | -3922 |
| Glucose With Non-fat Milk | -1235 |
| Glucose With Whey Protein Isolate | 195 |
| Glucose With Sodium Caseinate | -189 |
Plasma ADMA/arginine concentration, calculated as ADMA/ARG AUC from 0-180 minutes (NCT02482675)
Timeframe: ADMA/ARG area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | (nmol/L)/(umol/L)*min (Mean) |
|---|---|
| Glucose | 275 |
| Glucose With Non-fat Milk | 55 |
| Glucose With Whey Protein Isolate | 47 |
| Glucose With Sodium Caseinate | 25 |
Plasma CCK concentration, calculated as CCK AUC from 0-180 minutes (NCT02482675)
Timeframe: CCK area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | pmol/L*min (Mean) |
|---|---|
| Glucose | 89.67 |
| Glucose With Non-fat Milk | 422.87 |
| Glucose With Whey Protein Isolate | 352.5 |
| Glucose With Sodium Caseinate | 519.94 |
Plasma insulin concentration, calculated as insulin AUC from 0-180 minutes (NCT02482675)
Timeframe: Insulin area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | uIU/mL*min (Mean) |
|---|---|
| Glucose | 8179.7 |
| Glucose With Non-fat Milk | 8196.1 |
| Glucose With Whey Protein Isolate | 8654.6 |
| Glucose With Sodium Caseinate | 8656.9 |
Plasma MDA measured as MDA AUC from 0-180 minutes (NCT02482675)
Timeframe: Area under curve for MDA for three hours (0, 30, 60, 90, 120, 150, 180 min.) (change from baseline)
| Intervention | umol/L*min (Mean) |
|---|---|
| Glucose | 66.5 |
| Glucose With Non-fat Milk | 43.2 |
| Glucose With Whey Protein Isolate | 46.4 |
| Glucose With Sodium Caseinate | 45.1 |
NOx AUC for 0-180 minutes (NCT02482675)
Timeframe: Area under curve for nitrite/nitrate for three hours (0, 30, 60, 90, 120, 180 min) (change from baseline)
| Intervention | umol/L*min (Mean) |
|---|---|
| Glucose | -1363 |
| Glucose With Non-fat Milk | 347 |
| Glucose With Whey Protein Isolate | -21 |
| Glucose With Sodium Caseinate | -57.2 |
Plasma glucose concentration from 0-180 minutes (NCT02482675)
Timeframe: Area under the curve for glucose for three hours (0, 30, 60, 90, 120, 180 minutes) (change from baseline)
| Intervention | mg/dL*min (Mean) |
|---|---|
| Glucose | 5828 |
| Glucose With Non-fat Milk | 4032 |
| Glucose With Whey Protein Isolate | 3340 |
| Glucose With Sodium Caseinate | 3640 |
Plasma SDMA/arginine concentration, calculated as SDMA/ARG AUC from 0-180 minutes (NCT02482675)
Timeframe: SDMA/ARG area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | (nmol/L)/(umol/L)*min (Mean) |
|---|---|
| Glucose | 175 |
| Glucose With Non-fat Milk | 31 |
| Glucose With Whey Protein Isolate | 4 |
| Glucose With Sodium Caseinate | -17 |
Plasma BH4/BH2 concentration, calculated as BH4/BH2 AUC from 0-180 minutes (NCT02482675)
Timeframe: Plasma BH4/BH2 concentration area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | ratio*min (Mean) |
|---|---|
| Glucose | -47 |
| Glucose With Non-fat Milk | 78 |
| Glucose With Whey Protein Isolate | 171 |
| Glucose With Sodium Caseinate | 131 |
Flow mediated dilation (FMD) of the brachial artery, calculated as FMD AUC for 0-180 minutes (change from baseline) (NCT02482675)
Timeframe: Area under curve for FMD for three hours (0, 30, 60, 90, 120, 180 minutes)
| Intervention | %*min (Mean) |
|---|---|
| Glucose | -307 |
| Glucose With Non-fat Milk | -34.8 |
| Glucose With Whey Protein Isolate | -36.8 |
| Glucose With Sodium Caseinate | -110 |
2 reviews available for n(g),n(g')-dimethyl-l-arginine and Hyperglycemia
| Article | Year |
|---|---|
Post-challenge hyperglycaemia, nitric oxide production and endothelial dysfunction: the putative role of asymmetric dimethylarginine (ADMA).
Topics: Animals; Arginine; Diabetes Mellitus, Type 2; Endothelium, Vascular; Glucose; Glucose Tolerance Test | 2011 |
Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium.
Topics: Arginine; Biological Factors; Biomarkers; C-Reactive Protein; Cell Differentiation; Cell Proliferati | 2005 |
4 trials available for n(g),n(g')-dimethyl-l-arginine and Hyperglycemia
| Article | Year |
|---|---|
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus.
Topics: Acarbose; Aged; Arginine; Biomarkers; Blood Glucose; C-Reactive Protein; CD40 Ligand; Diabetes Melli | 2010 |
Postprandial hyperglycemia impairs vascular endothelial function in healthy men by inducing lipid peroxidation and increasing asymmetric dimethylarginine:arginine.
Topics: Adolescent; Adult; Area Under Curve; Arginine; Blood Glucose; Chromatography, High Pressure Liquid; | 2011 |
Supplementation of a γ-tocopherol-rich mixture of tocopherols in healthy men protects against vascular endothelial dysfunction induced by postprandial hyperglycemia.
Topics: Adolescent; Adult; Antioxidants; Arginine; Ascorbic Acid; Blood Glucose; Brachial Artery; Dietary Su | 2013 |
8 other studies available for n(g),n(g')-dimethyl-l-arginine and Hyperglycemia
| Article | Year |
|---|---|
Asymmetric dimethylarginine accumulation under hyperglycemia facilitates β-cell apoptosis via inhibiting nitric oxide production.
Topics: Animals; Apoptosis; Caspase 3; Glucose; Hyperglycemia; Mice; Nitric Oxide | 2022 |
Asymmetric dimethylarginine accumulation under hyperglycemia facilitates β-cell apoptosis via inhibiting nitric oxide production.
Topics: Animals; Apoptosis; Caspase 3; Glucose; Hyperglycemia; Mice; Nitric Oxide | 2022 |
Asymmetric dimethylarginine accumulation under hyperglycemia facilitates β-cell apoptosis via inhibiting nitric oxide production.
Topics: Animals; Apoptosis; Caspase 3; Glucose; Hyperglycemia; Mice; Nitric Oxide | 2022 |
Asymmetric dimethylarginine accumulation under hyperglycemia facilitates β-cell apoptosis via inhibiting nitric oxide production.
Topics: Animals; Apoptosis; Caspase 3; Glucose; Hyperglycemia; Mice; Nitric Oxide | 2022 |
Asymmetric dimethylarginine accumulation under hyperglycemia facilitates β-cell apoptosis via inhibiting nitric oxide production.
Topics: Animals; Apoptosis; Caspase 3; Glucose; Hyperglycemia; Mice; Nitric Oxide | 2022 |
Asymmetric dimethylarginine accumulation under hyperglycemia facilitates β-cell apoptosis via inhibiting nitric oxide production.
Topics: Animals; Apoptosis; Caspase 3; Glucose; Hyperglycemia; Mice; Nitric Oxide | 2022 |
Asymmetric dimethylarginine accumulation under hyperglycemia facilitates β-cell apoptosis via inhibiting nitric oxide production.
Topics: Animals; Apoptosis; Caspase 3; Glucose; Hyperglycemia; Mice; Nitric Oxide | 2022 |
Asymmetric dimethylarginine accumulation under hyperglycemia facilitates β-cell apoptosis via inhibiting nitric oxide production.
Topics: Animals; Apoptosis; Caspase 3; Glucose; Hyperglycemia; Mice; Nitric Oxide | 2022 |
Asymmetric dimethylarginine accumulation under hyperglycemia facilitates β-cell apoptosis via inhibiting nitric oxide production.
Topics: Animals; Apoptosis; Caspase 3; Glucose; Hyperglycemia; Mice; Nitric Oxide | 2022 |
An assessment of correlation between serum asymmetric dimethylarginine and glycated haemoglobin in patients with type 2 diabetes mellitus.
Topics: Arginine; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorben | 2014 |
Asymmetric dimethylarginine is negatively correlated with hyperglycemia in children.
Topics: Adolescent; Arginine; Biomarkers; Body Mass Index; Cardiovascular Diseases; Child; Cross-Sectional S | 2015 |
Ex vivo gene transferring of human dimethylarginine dimethylaminohydrolase-2 improved endothelial dysfunction in diabetic rat aortas and high glucose-treated endothelial cells.
Topics: Amidohydrolases; Animals; Aorta; Arginine; Diabetes Mellitus; Diabetes Mellitus, Experimental; Endot | 2010 |
Acute effects of hyperglycaemia on asymmetric dimethylarginine (ADMA), adiponectin and inflammatory markers (IL-6, hs-CRP) in overweight and obese women with metabolic syndrome.
Topics: Adiponectin; Adult; Aged; Arginine; Biomarkers; Female; Humans; Hyperglycemia; Interleukin-6; Metabo | 2010 |
Asymmetric dimethylarginine level in hyperglycemic gestation.
Topics: Adult; Arginine; Blood Glucose; Body Mass Index; Case-Control Studies; Chromatography, High Pressure | 2011 |
Intensive treatment of risk factors in patients with type-2 diabetes mellitus is associated with improvement of endothelial function coupled with a reduction in the levels of plasma asymmetric dimethylarginine and endogenous inhibitor of nitric oxide synt
Topics: Arginine; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Female; Humans; H | 2006 |
Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxan-induced hyperglycaemia.
Topics: Alloxan; Animals; Arginine; Blood Glucose; Body Weight; Carotid Arteries; Cyclic GMP; Endothelium, V | 1999 |